Ha habido 50 transacciones internas recientes registradas para Candel Therapeutics, Inc. (CADL), incluyendo 34 compras y 15 ventas. El total de compras internas fue valorado en $26.12M y el total de ventas internas en $1.25M.
Internos destacados con actividad reciente incluyen Papa Joseph C, Manning Paul B, Loggia Nicoletta. Las transacciones internas pueden proporcionar información sobre cómo la dirección de la empresa ve la valoración y perspectivas futuras de la acción.
Operaciones de Insiders — CADL
| Fecha |
Nombre |
Cargo |
Tipo de Transacción |
Acciones |
Precio Promedio |
Valor |
Acciones en Propiedad |
| 2026-03-31 |
Papa Joseph C |
Director |
Concesión de RSU |
2,795 |
$4.90 |
$13.7K |
2,795 |
| 2026-03-31 |
Manning Paul B |
Director |
Concesión de RSU |
4,618 |
$4.90 |
$22.63K |
4,618 |
| 2026-03-31 |
Loggia Nicoletta |
Director |
Concesión de RSU |
779 |
$4.90 |
$3.82K |
779 |
| 2026-02-23 |
Manning Paul B |
Director |
Compra Informativa |
550,458 |
$5.45 |
$3M |
2,763,527 |
| 2026-01-26 |
Nichols William Garrett |
Chief Medical Officer |
Concesión de RSU |
136,500 |
$6.01 |
$820.37K |
136,500 |
| 2026-01-26 |
Tak Paul Peter |
Chief Executive Officer |
Concesión de RSU |
629,000 |
$6.01 |
$3.78M |
629,000 |
| 2026-01-26 |
Barone Francesca |
Chief Scientific Officer |
Concesión de RSU |
232,000 |
$6.01 |
$1.39M |
232,000 |
| 2026-01-26 |
Tyagarajan Seshu |
Chief Technology Officer |
Concesión de RSU |
154,000 |
$6.01 |
$925.54K |
154,000 |
| 2026-01-26 |
Schoch Charles |
Chief Financial Officer |
Concesión de RSU |
232,000 |
$6.01 |
$1.39M |
232,000 |
| 2025-07-28 |
Nichols William Garrett |
Chief Medical Officer |
Ejercicio de Opciones (Venta) |
937 |
$1.29 |
$1.21K |
29,377 |
| 2025-06-30 |
Nichols William Garrett |
Chief Medical Officer |
Ejercicio de Opciones (Venta) |
781 |
$1.29 |
$1.01K |
30,314 |
| 2025-06-25 |
Papa Joseph C |
Director |
Concesión de RSU |
64,239 |
$4.67 |
$300K |
64,239 |
| 2025-06-25 |
Manning Paul B |
Director |
Concesión de RSU |
1,070,663 |
$4.67 |
$5M |
2,213,069 |
| 2025-06-25 |
Nabel Gary J. |
Director |
Concesión de RSU |
5,353 |
$4.67 |
$25K |
5,353 |
| 2025-06-25 |
Martell Christopher |
Director |
Concesión de RSU |
111,349 |
$4.67 |
$520K |
111,349 |
| 2025-06-25 |
Tak Paul Peter |
Chief Executive Officer |
Concesión de RSU |
42,826 |
$4.67 |
$200K |
268,566 |
| 2025-06-25 |
Barone Francesca |
Chief Scientific Officer |
Concesión de RSU |
4,282 |
$4.67 |
$20K |
100,809 |
| 2025-06-25 |
Tyagarajan Seshu |
Chief Technology Officer |
Concesión de RSU |
5,353 |
$4.67 |
$25K |
90,865 |
| 2025-06-25 |
Loggia Nicoletta |
Director |
Concesión de RSU |
2,141 |
$4.67 |
$10K |
2,141 |
| 2025-06-25 |
Schoch Charles |
Chief Financial Officer |
Concesión de RSU |
5,353 |
$4.67 |
$25K |
43,391 |
| 2025-06-20 |
Schoch Charles |
Chief Financial Officer |
Concesión de RSU |
50,000 |
$4.75 |
$237.5K |
50,000 |
| 2025-06-17 |
Papa Joseph C |
Director |
Concesión de RSU |
14,240 |
$4.94 |
$70.35K |
14,240 |
| 2025-06-17 |
Manning Paul B |
Director |
Concesión de RSU |
14,240 |
$4.94 |
$70.35K |
14,240 |
| 2025-06-17 |
Benz Edward J. Jr |
Director |
Concesión de RSU |
14,240 |
$4.94 |
$70.35K |
14,240 |
| 2025-06-17 |
Gaeta Renee |
Director |
Concesión de RSU |
14,240 |
$4.94 |
$70.35K |
14,240 |
| 2025-06-17 |
Nguyen Diem |
Director |
Concesión de RSU |
14,240 |
$4.94 |
$70.35K |
14,240 |
| 2025-06-17 |
Nabel Gary J. |
Director |
Concesión de RSU |
14,240 |
$4.94 |
$70.35K |
14,240 |
| 2025-06-17 |
Martell Christopher |
Director |
Concesión de RSU |
14,240 |
$4.94 |
$70.35K |
14,240 |
| 2025-06-17 |
Loggia Nicoletta |
Director |
Concesión de RSU |
14,240 |
$4.94 |
$70.35K |
14,240 |
| 2025-06-04 |
Radhakrishnan Maha |
Officer |
Desconocido |
- |
- |
- |
- |
| 2025-06-04 |
Radhakrishnan Maha |
Director |
Concesión de RSU |
28,480 |
$5.60 |
$159.49K |
28,480 |
| 2025-03-19 |
Tak Paul Peter |
Chief Executive Officer |
Venta Informativa |
400 |
$9.00 |
$3.6K |
225,740 |
| 2025-03-18 |
Nichols William Garrett |
Chief Medical Officer |
Ejercicio de Opciones (Venta) |
13,905 |
$1.29 |
$17.94K |
31,095 |
| 2025-03-18 |
Tak Paul Peter |
Chief Executive Officer |
Venta Informativa |
25,772 |
$8.77 |
$226.02K |
226,140 |
| 2025-03-18 |
Barone Francesca |
Chief Scientific Officer |
Ejercicio de Opciones (Venta) |
18,000 |
$1.55 |
$27.9K |
30,822 |
| 2025-03-17 |
Tyagarajan Seshu |
Chief Technology Officer |
Ejercicio de Opciones (Venta) |
20,000 |
$1.29 |
$25.8K |
70,000 |
| 2025-03-17 |
Schoch Charles |
See Remarks |
Venta Informativa |
5,000 |
$8.83 |
$44.17K |
38,038 |
| 2025-03-17 |
Tyagarajan Seshu |
Chief Technology Officer |
Ejercicio de Opciones |
20,000 |
$1.29 |
$25.8K |
116,790 |
| 2025-02-21 |
Aguilar-cordova Estuardo |
10 Percent Owner |
Devolución de Acciones |
10,582 |
$12.02 |
$127.2K |
120,861 |
| 2025-02-12 |
Nichols William Garrett |
Chief Medical Officer |
Concesión de RSU |
107,250 |
$8.55 |
$916.99K |
107,250 |
| 2025-02-12 |
Tak Paul Peter |
Chief Executive Officer |
Concesión de RSU |
525,000 |
$8.55 |
$4.49M |
525,000 |
| 2025-02-12 |
Barone Francesca |
Chief Scientific Officer |
Concesión de RSU |
115,000 |
$8.55 |
$983.25K |
115,000 |
| 2025-02-12 |
Tyagarajan Seshu |
Chief Technology Officer |
Concesión de RSU |
65,000 |
$8.55 |
$555.75K |
65,000 |
| 2025-02-12 |
Schoch Charles |
See Remarks |
Concesión de RSU |
83,000 |
$8.55 |
$709.65K |
83,000 |
| 2025-02-10 |
Aguilar-cordova Estuardo |
10 Percent Owner |
Devolución de Acciones |
31,335 |
$8.61 |
$269.79K |
60,000 |
| 2025-01-15 |
Nichols William Garrett |
Chief Medical Officer |
Venta Informativa |
10,428 |
$7.23 |
$75.34K |
79,320 |
| 2025-01-15 |
Tak Paul Peter |
Chief Executive Officer |
Venta Informativa |
21,704 |
$7.23 |
$156.81K |
251,912 |
| 2025-01-15 |
Barone Francesca |
Chief Scientific Officer |
Venta Informativa |
13,534 |
$7.23 |
$97.78K |
110,673 |
| 2025-01-15 |
Tyagarajan Seshu |
Chief Technology Officer |
Venta Informativa |
14,322 |
$7.23 |
$103.48K |
96,790 |
| 2025-01-15 |
Schoch Charles |
See Remarks |
Venta Informativa |
9,511 |
$7.23 |
$68.72K |
43,038 |
■ Informativa — transacción en mercado abierto (más significativa)
■ No informativa (compra) — premio, ejercicio de opción, conversión
■ No informativa (venta) — retención fiscal, venta de adjudicación
■ Neutral — regalo, fideicomiso, vencimiento
